000169710 001__ 169710
000169710 005__ 20240229133654.0
000169710 0247_ $$2doi$$a10.1038/s41416-021-01473-z
000169710 0247_ $$2pmid$$apmid:34215852
000169710 0247_ $$2ISSN$$a0007-0920
000169710 0247_ $$2ISSN$$a1532-1827
000169710 0247_ $$2altmetric$$aaltmetric:108607060
000169710 037__ $$aDKFZ-2021-01517
000169710 041__ $$aEnglish
000169710 082__ $$a610
000169710 1001_ $$0P:(DE-He78)820d29ab03f702f61c6c92df377d2846$$aLiu, Zhunzhun$$b0$$eFirst author$$udkfz
000169710 245__ $$aPrevalence of benefit finding and posttraumatic growth in long-term cancer survivors: results from a multi-regional population-based survey in Germany.
000169710 260__ $$aEdinburgh$$bNature Publ. Group$$c2021
000169710 3367_ $$2DRIVER$$aarticle
000169710 3367_ $$2DataCite$$aOutput Types/Journal article
000169710 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1642584936_1939
000169710 3367_ $$2BibTeX$$aARTICLE
000169710 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000169710 3367_ $$00$$2EndNote$$aJournal Article
000169710 500__ $$a#EA:C071#LA:C071# /  volume 125, pages 877–883 (2021)
000169710 520__ $$aCancer studies reported mixed results on benefit finding (BF) and posttraumatic growth (PTG) prevalence and few were focused on long-term survivors.BF and PTG were assessed in a multi-regional population-based study in Germany with 6952 breast, colorectal and prostate cancer survivors, using the Benefit Finding Scale and Posttraumatic Growth Inventory. We calculated the age-adjusted prevalence, stratified by demographical and clinical characteristics.Overall, 66.0% of cancer survivors indicated moderate-to-high BF, and 20.5% moderate-to-high PTG. Age-adjusted prevalence of BF and PTG differed according to cancer type (breast > colorectal > prostate) and sex (female > male). BF and PTG prevalence were higher in younger than in older respondents; the age-adjusted prevalence was higher in respondents who survived more years after diagnosis. The strength and direction of associations of age-adjusted prevalence with cancer stage, disease recurrence, and time since diagnosis varied according to cancer type and sex.A substantial proportion of long-term cancer survivors reported moderate-to-high BF and PTG. However, the prevalence was lower in older and male cancer survivors, and during the earlier years after cancer diagnosis. Further longitudinal studies on PTG and BF in cancer survivors are warranted to address heterogeneity in survivors' experience after cancer diagnosis.
000169710 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000169710 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo01.inet.dkfz-heidelberg.de
000169710 7001_ $$0P:(DE-He78)24fe6057396bec79d2638615b12eb989$$aThong, Melissa S Y$$b1$$udkfz
000169710 7001_ $$0P:(DE-He78)55389e9f54d8411e6e6eddcec489bb1b$$aDoege, Daniela$$b2$$udkfz
000169710 7001_ $$0P:(DE-He78)13aa5fe9d9961c9fd67193befb0dcf88$$aKoch-Gallenkamp, Lena$$b3$$udkfz
000169710 7001_ $$aBertram, Heike$$b4
000169710 7001_ $$aEberle, Andrea$$b5
000169710 7001_ $$aHolleczek, Bernd$$b6
000169710 7001_ $$aWaldmann, Annika$$b7
000169710 7001_ $$aZeissig, Sylke Ruth$$b8
000169710 7001_ $$aPritzkuleit, Ron$$b9
000169710 7001_ $$0P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aBrenner, Hermann$$b10$$udkfz
000169710 7001_ $$0P:(DE-He78)d023fdf423d87ee6c710e34dd7581fa0$$aArndt, Volker$$b11$$eLast author$$udkfz
000169710 773__ $$0PERI:(DE-600)2002452-6$$a10.1038/s41416-021-01473-z$$p877–883$$tBritish journal of cancer$$v125$$x1532-1827$$y2021
000169710 909CO $$ooai:inrepo02.dkfz.de:169710$$pVDB
000169710 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)820d29ab03f702f61c6c92df377d2846$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000169710 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)24fe6057396bec79d2638615b12eb989$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000169710 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)55389e9f54d8411e6e6eddcec489bb1b$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000169710 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)13aa5fe9d9961c9fd67193befb0dcf88$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000169710 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aDeutsches Krebsforschungszentrum$$b10$$kDKFZ
000169710 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)d023fdf423d87ee6c710e34dd7581fa0$$aDeutsches Krebsforschungszentrum$$b11$$kDKFZ
000169710 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000169710 9130_ $$0G:(DE-HGF)POF3-313$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vCancer risk factors and prevention$$x0
000169710 9141_ $$y2021
000169710 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bBRIT J CANCER : 2019$$d2021-01-28
000169710 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2021-01-28
000169710 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2021-01-28
000169710 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2021-01-28
000169710 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2021-01-28
000169710 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2021-01-28
000169710 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2021-01-28
000169710 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2021-01-28
000169710 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-01-28
000169710 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2021-01-28
000169710 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2021-01-28
000169710 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2021-01-28
000169710 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-01-28
000169710 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2021-01-28
000169710 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bBRIT J CANCER : 2019$$d2021-01-28
000169710 9201_ $$0I:(DE-He78)C071-20160331$$kC071$$lC071 Cancer Survivorship$$x0
000169710 9201_ $$0I:(DE-He78)C070-20160331$$kC070$$lC070 Klinische Epidemiologie und Alternf.$$x1
000169710 9201_ $$0I:(DE-He78)C120-20160331$$kC120$$lPräventive Onkologie$$x2
000169710 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x3
000169710 980__ $$ajournal
000169710 980__ $$aVDB
000169710 980__ $$aI:(DE-He78)C071-20160331
000169710 980__ $$aI:(DE-He78)C070-20160331
000169710 980__ $$aI:(DE-He78)C120-20160331
000169710 980__ $$aI:(DE-He78)HD01-20160331
000169710 980__ $$aUNRESTRICTED